Status:
NOT_YET_RECRUITING
HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.
Lead Sponsor:
University of Zurich
Collaborating Sponsors:
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Conditions:
High Altitude Pulmonary Hypertension
Sleep Apnea
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the current study is to evaluate the clinical and physiologic course of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study. To...
Eligibility Criteria
Inclusion
- Permanently living \>2500 m
- Written informed consent
Exclusion
- Highlanders who cannot follow the study investigations,
- Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking \>20 cigarettes/day or \>20 pack-years.
- Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months
- Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)
Key Trial Info
Start Date :
July 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06489730
Start Date
July 1 2024
End Date
December 31 2024
Last Update
July 8 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.